GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Merus NV (NAS:MRUS) » Definitions » Beneish M-Score

MRUS (Merus NV) Beneish M-Score : -2.76 (As of Dec. 13, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Merus NV Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.76 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Merus NV's Beneish M-Score or its related term are showing as below:

MRUS' s Beneish M-Score Range Over the Past 10 Years
Min: -3.54   Med: -2.02   Max: 20.26
Current: -2.76

During the past 12 years, the highest Beneish M-Score of Merus NV was 20.26. The lowest was -3.54. And the median was -2.02.


Merus NV Beneish M-Score Historical Data

The historical data trend for Merus NV's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merus NV Beneish M-Score Chart

Merus NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.40 -3.02 -0.30 -2.36 -2.56

Merus NV Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.85 -2.56 7.62 -2.98 -2.76

Competitive Comparison of Merus NV's Beneish M-Score

For the Biotechnology subindustry, Merus NV's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Merus NV's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Merus NV's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Merus NV's Beneish M-Score falls into.



Merus NV Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Merus NV for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0714+0.528 * 1+0.404 * 1.423+0.892 * 0.7867+0.115 * 0.8667
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.6127+4.679 * -0.065542-0.327 * 0.6959
=-2.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Total Receivables was $3.88 Mil.
Revenue was 11.772 + 7.332 + 7.889 + 8.939 = $35.93 Mil.
Gross Profit was 11.772 + 7.332 + 7.889 + 8.939 = $35.93 Mil.
Total Current Assets was $666.28 Mil.
Total Assets was $844.68 Mil.
Property, Plant and Equipment(Net PPE) was $22.46 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.50 Mil.
Selling, General, & Admin. Expense(SGA) was $75.26 Mil.
Total Current Liabilities was $80.08 Mil.
Long-Term Debt & Capital Lease Obligation was $9.28 Mil.
Net Income was -99.905 + -50.042 + -34.456 + -60.153 = $-244.56 Mil.
Non Operating Income was -34.95 + 9.519 + 8.534 + -16.772 = $-33.67 Mil.
Cash Flow from Operations was -80.422 + 5.633 + -44.388 + -36.348 = $-155.53 Mil.
Total Receivables was $4.61 Mil.
Revenue was 11.033 + 10.476 + 13.499 + 10.666 = $45.67 Mil.
Gross Profit was 11.033 + 10.476 + 13.499 + 10.666 = $45.67 Mil.
Total Current Assets was $404.83 Mil.
Total Assets was $492.19 Mil.
Property, Plant and Equipment(Net PPE) was $23.50 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.23 Mil.
Selling, General, & Admin. Expense(SGA) was $59.32 Mil.
Total Current Liabilities was $64.32 Mil.
Long-Term Debt & Capital Lease Obligation was $10.51 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(3.883 / 35.932) / (4.607 / 45.674)
=0.108065 / 0.100867
=1.0714

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(45.674 / 45.674) / (35.932 / 35.932)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (666.276 + 22.458) / 844.676) / (1 - (404.832 + 23.499) / 492.186)
=0.184618 / 0.129738
=1.423

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=35.932 / 45.674
=0.7867

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(2.234 / (2.234 + 23.499)) / (2.5 / (2.5 + 22.458))
=0.086815 / 0.100168
=0.8667

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(75.262 / 35.932) / (59.323 / 45.674)
=2.094568 / 1.298835
=1.6127

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((9.284 + 80.076) / 844.676) / ((10.506 + 64.318) / 492.186)
=0.105792 / 0.152024
=0.6959

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-244.556 - -33.669 - -155.525) / 844.676
=-0.065542

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Merus NV has a M-score of -2.76 suggests that the company is unlikely to be a manipulator.


Merus NV Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Merus NV's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Merus NV Business Description

Traded in Other Exchanges
Address
Uppsalalaan 17, Utrecht, NLD, 3584 CT
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
Executives
Harry Shuman officer: Chief Accounting Officer C/O MERUS N.V., VALELAAN 62, UTRECHT P7 3584 CM
Peter B. Silverman officer: EVP & General Counsel C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM
Sven Ante Lundberg director, officer: President, CEO & PFO C/O CRISPR THERAPEUTICS AG, 200 SIDNEY STREET, CAMBRIDGE MA 02139
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Kruif John De officer: Chief Technology Officer C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM
Paolo Pucci director C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Len Kanavy director C/O MERUS N.V., VALELAAN 62, UTRECHT P7 3584 CM
Maxine Gowen director
Anand Mehra director 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Victor Sandor director C/O ARRAY BIOPHARMA INC., 3200 WALNUT STREET, BOULDER CO 80301
Mark T Iwicki director 84 WATERFORD DRIVE, MARLBOROUGH MA 01752
Gregory D Perry director C/O IMMUNOGEN, INC., 830 WINTER ST., WALTHAM MA 02451
Geuijen Cecile A W officer: SVP & Chief Scientific Officer C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584CM
Andrew Joe officer: SVP, CMO C/O MERUS N.V., VALELAAN 62, UTRECHT P7 3584 CM
Mark Throsby officer: EVP & Chief Scientific Officer C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM